Lv55
950 积分 2025-08-25 加入
Dose-dense neoadjuvant bi-weekly nab-paclitaxel followed by epirubicin-cyclophosphamide versus bi-weekly docetaxel followed by epirubicin-cyclophosphamide in patients with HR+/HER2- early breast cancer: a multicentre, randomised, phase III trial
23小时前
待确认
Role of individualized intervention(s) on quality of life and adherence to adjuvant endocrine therapy in premenopausal women with early-stage breast cancer: MyCHOICE study
23小时前
待确认
The impact of menopausal status on the efficacy of adjuvant CDK4/6 inhibitors in hormone receptor–positive early breast cancer: a systematic review and meta-analysis of phase III clinical trials
1天前
待确认
70-gene signature MammaPrint for early-stage HR-positive, HER2-negative breast cancer: Outcome in the MINDACT trial for key clinical-pathological high-risk subgroups
1天前
待确认
Izalontamab brengitecan for HR+/HER2– breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial
10天前
已完结
Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial
10天前
已完结
Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer
10天前
已完结
Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer
10天前
已完结
Systemic Therapy Considerations in Older Adults With Early-Stage Breast Cancer: A Review
15天前
已关闭
Diagnostic performance of axillary ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer patients - Results from the prospective AXSANA registry trial
17天前
已完结
蔚蓝之下,谁是海洋中的常住“居民”?
2个月前
已采纳